Welcome to our dedicated page for Amgen SEC filings (Ticker: AMGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
Amgen Inc. executive David M. Reese reported routine tax-related share dispositions. On May 2, 2026, a total of 1,433 shares of Amgen common stock were withheld at $329.82 per share to cover tax obligations, classified as tax-withholding dispositions rather than open-market sales.
A footnote notes that the reported holdings include 442 Dividend Equivalents tied to unvested Restricted Stock Units, which will be paid in common shares on a one-to-one basis as those units vest.
Amgen Inc. senior vice president of human resources Derek Miller reported routine share dispositions tied to tax withholding, not open-market sales. On May 2, 2026, a total of 365 shares of Amgen common stock were withheld at $329.82 per share to cover tax liabilities on equity awards.
A footnote explains that his holdings include 123 Dividend Equivalents credited under Amgen’s equity incentive plan, which will be paid out as common shares on a one-for-one basis as related restricted stock units vest.
Amgen Inc. SVP Rachna Khosla reported routine tax-withholding share dispositions. On May 2, 2026, a total of 225 shares of Amgen common stock were withheld at $329.82 per share to cover tax liabilities tied to equity awards, not as open-market sales. She continues to hold a direct stake in Amgen stock, and her holdings also reflect 73 dividend equivalents linked to unvested restricted stock units that will settle in shares as they vest.
Amgen Inc. senior vice president and chief compliance officer Nancy A. Grygiel reported multiple transactions in the company’s common stock. On May 4, 2026, she completed an open-market sale of 1,237 shares at an average price of $323.7272 per share. On May 2, 2026, two F-code tax-withholding dispositions of 116 and 126 shares at $329.82 per share were recorded to cover tax obligations. After these transactions, she directly holds 7,009 shares of Amgen common stock and has an additional 106.1864 shares indirectly through the company’s 401(k) Plan. Her holdings also reflect 72 Dividend Equivalents tied to unvested restricted stock units that pay out in shares as they vest.
Amgen Inc. EVP & CFO Peter H. Griffith reported two tax-related share dispositions of company common stock. On May 2, 2026, he delivered 687 shares and 746 shares of Amgen stock at $329.82 per share each as tax-withholding transactions, not open-market sales.
After these dispositions, his reported direct holdings in Amgen common stock were 47,568 shares following one transaction and 48,255 shares following the other. A footnote notes that his holdings include 454 Dividend Equivalents tied to unvested Restricted Stock Units under Amgen’s equity incentive plan, which pay out in shares as the awards vest.
Amgen Inc. executive vice president and general counsel Jonathan P. Graham reported two routine tax-related share dispositions. On May 2, 2026, a total of 1,257 shares of Amgen common stock were withheld at $329.82 per share to satisfy tax obligations on equity awards, rather than sold on the open market. Following these transactions, his reported direct holdings in the affected accounts were 38,010 and 38,620 shares of common stock.
Amgen Inc. executive Gordon Murdo reported routine tax-related share dispositions, not open-market sales. On May 2, 2026, he had 1,593 shares of common stock withheld at $329.82 per share to cover tax obligations. Following these transactions, he directly holds 49,462 Amgen shares.
A footnote explains his holdings include 488 Dividend Equivalents tied to unvested Restricted Stock Units under Amgen’s equity incentive plan, which pay out in shares according to the vesting schedule.
Amgen Inc. vice president, finance and chief accounting officer Matthew C. Busch reported routine share dispositions related to tax withholding. On May 2, 2026, a total of 68 shares of common stock were withheld at $329.82 per share to satisfy tax obligations tied to equity awards.
Following these transactions, Busch directly holds 4,018 shares of Amgen common stock. A footnote explains that his holdings include 49 Dividend Equivalents linked to unvested Restricted Stock Units, which will be settled in common shares as those units vest.
AMGEN INC Chairman, CEO and President Robert A. Bradway reported routine equity-related activity in company stock. The filing shows tax-withholding dispositions totaling 5,057 shares of common stock at $329.82 per share, used to cover exercise price or tax liabilities tied to equity awards.
Bradway also reports indirect holdings in Amgen common stock through his spouse and related GRATs, alongside Dividend Equivalents credited to unvested Restricted Stock Units that pay out in shares as they vest. These transactions do not reflect open-market buying or selling decisions.